Live Quote · NASDAQCRDFHealthcare· Biotechnology

Cardiff Oncology, Inc.

$1.27 1.55%($-0.02)
TickerSpark Score
45/100
Weak
40
Valuation
20
Profitability
55
Growth
80
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRDF research report →

52-Week Range3% of range
Low
$1.16
Current
$1.27
High
$4.56
Company Overviewwww.cardiffoncology.com

About the company

Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.

CEO
Mani Mohindru
IPO
2004
Employees
31
HQ
San Diego, CA, US

Price Chart

-64.62% · this period
$4.45$2.81$1.18Jul 02Dec 31Jul 02
Valuation
Market Cap
$86.83M
P/E
-1.90
P/S
165.39
P/B
2.50
EV/EBITDA
-1.80
Div Yield
0.00%
Profitability
Gross Margin
-2105.71%
Op Margin
-9033.90%
Net Margin
-8526.10%
ROE
-95.50%
ROIC
-134.15%
Growth & Income
Revenue
$593.00K · -13.18%
Net Income
$-45,851,000 · -0.92%
EPS
$-0.69 · 27.37%
Op Income
$-48,960,000
FCF YoY
-0.51%
Performance & Tape
52W High
$4.56
52W Low
$1.16
50D MA
$1.56
200D MA
$1.99
Beta
1.38
Avg Volume
1.22M

Get TickerSpark's AI analysis on CRDF

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 18, 26Mohindru Manibuy24,703
Jun 18, 26PACE GARY Wbuy30,000
Jun 11, 26Armitage James Oother40,565
Jun 11, 26White Laleother40,565
Jun 11, 26TANNENBAUM RENEE Pother40,565
Jun 11, 26Markin Rodney Sother40,565
Jun 11, 26PACE GARY Wother40,565
Apr 27, 26Aggarwal Ajayother400,000
Apr 27, 26Aggarwal Ajayother0
Apr 6, 26Muntner Joshua Bother0
Coverage · CRDF

Our CRDF coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on CRDF yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate CRDF report →
Internal Compare

Similar companies

Peers in the same neighborhood.